Press Releases

Press Releasesmckinleymedia2019-03-05T14:25:59-08:00

2Apr, 2019

Personalis Appoints Industry Executive Aaron Tachibana as Chief Financial Officer

31Mar, 2019

Personalis, Inc. to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019

18Mar, 2019

Personalis to Present at ICI-IO Combinations Summit 2019

28Feb, 2019

Personalis, Inc. to Present at the World Immunotherapy Congress USA 2019

5Feb, 2019

Personalis to Present at the 2019 Immuno-Oncology 360 Conference in New York

3Jan, 2019

Personalis Appoints Biotech Industry Executive Clinton Musil as Chief Business Officer

27Nov, 2018

Personalis to Present at the 4th Annual ICI Europe Summit 2018 in Berlin

14Nov, 2018

Personalis, Inc. to Present at the 3rd Annual NeoAG Summit Boston

9Nov, 2018

Personalis Launches ImmunoID NeXT, the First Platform Providing Characterization of a Tumor and its Microenvironment from a Single Sample

6Nov, 2018

Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer’s (SITC) 33RD Annual Meeting

9Oct, 2018

Personalis Receives New Order from the VA’s Million Veteran Program – Total Contracted Now Almost 80,000 Whole Human Genomes

12Sep, 2018

Personalis, Inc. to Present at Rational Combinations 360 in Philadelphia

30Aug, 2018

Personalis, Inc. to Present at the 6th Annual Immuno-Oncology Summit, Boston, MA

26Jul, 2018

Personalis, Inc. Receives Approval from the New York State Department of Health for Use of its ACE ImmunoID™ Platform in Cancer Immunotherapeutic Clinical Trials

15May, 2018

Personalis, Inc. Expands International Recognition of ACE© Technology with the Issuance of Chinese Patent, adding to US and UK Patents

24Apr, 2018

Personalis Clinical Laboratory Receives Accreditation from College of American Pathologists

16Apr, 2018

Personalis, Inc. to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting 2018

8Feb, 2018

Personalis, Inc. Releases the Latest Version of NeoantigenID™ for Enhanced Neoantigen Identification on the ACE ImmunoID™ Platform

6Feb, 2018

Personalis, Inc. Launches ImmunogenomicsID™ for Multidimensional Immuno-Oncology Biomarker Analysis as the Latest Enhancement to the ACE ImmunoID™ Platform

30Nov, 2017

Personalis Awarded New Contract with the US Department of Veterans Affairs to Provide Clinical Cancer Genomic Testing and Analysis for the Precision Oncology Program

16Nov, 2017

Personalis, Inc. Launches Early Access Program for Cell-Free DNA ACE Exome for Tumor Neoantigens

14Nov, 2017

Dr. Richard Chen, Chief Scientific Officer, Personalis, Inc. to Present Data and Discuss Tumor Immuno-genomics and Personalized Vaccines Solutions at 2017 Neoantigen Summit

7Nov, 2017

Personalis Wins New Contract to Sequence >34,000 Whole Human Genomes for the VA’s Million Veteran Program

24Apr, 2017

Personalis, Inc. Receives Approval from the New York State Department of Health for Clinical Tests Based on the ACE Exome

20Apr, 2017

Personalis Inc. Orders Ten Illumina NovaSeq™ 6000 Systems for Immuno-Oncology Genomics and Large-Scale Whole Genome Sequencing